Elizabeth P. Gould

发表

Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB‐756050, in Type 2 Diabetes

D. Nunez, L. V. Vasist Johnson, G. Bowers, 2013, Clinical pharmacology in drug development.

Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.

J. Gallant, R. Grant, I. Frank, 2017, The lancet. HIV.

Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults

S. Piscitelli, P. Williams, H. Crauwels, 2014, Journal of acquired immune deficiency syndromes.

Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam

J. Polli, M. Reese, J. Humphreys, 2016, Xenobiotica; the fate of foreign compounds in biological systems.

Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans

S. Piscitelli, M. Reese, W. Spreen, 2016, Xenobiotica; the fate of foreign compounds in biological systems.

Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744

S. Piscitelli, H. Crauwels, W. Spreen, 2013, Antimicrobial Agents and Chemotherapy.

Effects of Etravirine on the Pharmacokinetics of the Integrase Inhibitor S/GSK1265744

S. Piscitelli, W. Spreen, E. Dumont, 2012, Antimicrobial Agents and Chemotherapy.

GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects

S. Piscitelli, D. Wilfret, W. Spreen, 2014, Journal of acquired immune deficiency syndromes.

Relative Bioavailability of an Emulsion Formulation for Omega‐3‐Acid Ethyl Esters Compared to the Commercially Available Formulation: A Randomized, Parallel‐Group, Single‐Dose Study Followed by Repeat Dosing in Healthy Volunteers

W. Harris, F. Gao, M. Fossler, 2012, Clinical pharmacology in drug development.

The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects

S. Baldwin, M. Davies, Mark Johnson, 2018, Pharmacology research & perspectives.

Zanamivir Pharmacokinetics and Pulmonary Penetration into Epithelial Lining Fluid following Intravenous or Oral Inhaled Administration to Healthy Adult Subjects

M. Shelton, K. Rodvold, Lori S. Jones, 2011, Antimicrobial Agents and Chemotherapy.

Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects

W. Spreen, Y. Lou, S. Ford, 2016, Clinical pharmacology in drug development.

Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.

S. Piscitelli, D. Mayers, Scott White, 2012, British Journal of Clinical Pharmacology.

Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol‐containing oral contraceptive in healthy adult women

J. Ritter, W. Spreen, P. Patel, 2017, British journal of clinical pharmacology.

Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.

J. Gallant, R. Grant, I. Frank, 2017, The lancet. HIV.